Open AccessImmunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
Author(s) -
Tri Juli Edi Tarigan,
Adisti Dwijayanti,
Susie Setyowati,
Melva Louisa
Publication year - 2021
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s279385
Subject(s) - medicine , insulin glargine , insulin , diabetes mellitus , type 2 diabetes , adverse effect , immunogenicity , postprandial , gastroenterology , endocrinology , hypoglycemia , antibody , immunology
To compare the immunogenicity and efficacy of insulin glargine biosimilar Ezelin (EZL) versus originator insulin glargine Lantus (LAN) as a reference basal insulin in patients with type 2 diabetes (T2D).